relatives share genes with their affected family member, but do not share the disease process, abnormalities present in relatives are likely associated with the genes for schizophrenia. Results: Evidence was found for disease-specific, genetic risk and compensatory brain mechanisms associated with schizophrenia that were complementary between the results from brain morphology, structural connectivity, and brain functioning. Discussion: Isolating the biological and genetic basis of these deficits could ultimately aid in developing novel psychosocial and pharmacological treatments to facilitate improved day-to-day functioning in schizophrenia.
biomarkers, thought to represent antibodies selectively depleted from the blood due to target binding in tissues, had less replicability and utility than expression biomarkers, which may offer insights into the active role of the adaptive immune system in psychosis. Further work will attempt to validate this approach in larger samples, using psychiatric disease controls. This autoantibodyomic approach may also show promise for the identification of predictive and prognostic biomarkers in psychotic disorders. Background: Major depressive disorder (MDD) is one of the most common mental disorders, with a lifetime prevalence of 14.6%. The impact of depression is considerable; poor social and economic functioning and significant life limitations [1] . Depression is also the most common co-morbidity seen with other mental disorders. The prevalence of depressive disorder in schizophrenia has been reported to be around 40% [2] . When examining very early phases of illness, in groups identified as at clinical high risk (CHR) for psychosis, high rates of 'co-morbid' axis one diagnoses are reported, with over 50% reaching criteria for a depressive disorder. Those people with schizophrenia send depression are significantly more likely to relapse, to be a safety concern (be arrested, victimized or suicidal), have greater substance-related problems and poorer recovery [2] . In addition, depression has been linked to increased risk of transition from CHR to FEP, suggesting that in this group depression also indicates a poorer outcome [3] . Currently, the diagnosis of depression is based on the phenomenological evaluation of symptoms and behavior. However, there remains significant debate around the heterogeneity of depressive symptoms and their function as prognostic indicators [4] . Neuroimaging holds "diagnostic potential" for depression [5] . However, studies show that brain alterations are often small and reliability is difficult, and there has been no neuroimaging investigation of depression as a co-morbid diagnosis. We aim to further understand the symptom profile of depression in emerging mental disorders, including in the clinical high risk group (CHR) and recent onset psychosis (ROP) as compared to those with recent onset depression (ROD). This has important implications for the accurate identification of a potentially malleable target for treatment, and indeed development of novel therapeutic options. We also aim to explore the ability of brain imagining (structural MRI) to add accuracy to the classification prediction models Methods: Data from the PRONIA study, an EUFP7 funded 8 center study recruiting ROD, CHR and ROP participants will be presented. Analysis will include demographic information and BDI-II (Beck Depression Inventory), CAARMS (Comprehensive Assessment of the At Risk Mental State), SANS (Scale for the assessment of negative symptoms) total score PANSS (Positive and negative Symptom Score) and SPI-A together with structural MRI imaging. We will report descriptive detail from the PRONIA discovery sample (n716), machine learning classification with Neurominer® and VBM analysis of sMRI scans across groups. Results: Data from BDI-II symptom endorsement suggests a 'classical depression phenotype' corresponding to Becks 'cognitive triad'; "life is pointless, future hopeless, self as worthless" may separate depression in ROD from ROP, with other symptoms potentially able to separate ROP from ROD. In classification, a 65% sensitivity and specificity are found. Data will also be presented on the CHR group and their alignment, together with VBM analysis for structural MRI examining correlates with highly weighted classifying symptoms in and across all three groups. Discussion: When given early in the course of illness, interventions have the greatest potential impact, and characterization and accurate diagnosis of depression in emerging mental disorders is an important goal. This study suggests it may be possible to accurately identify depression in different diagnostic categories, including major depressive disorder, psychosis and clinical high risk, and that neuroimaging holds potential to add to diagnostic accuracy in complex co-morbid disorders. Methods: Blood samples were collected from patients in FEP (n = 35) after their first contact with the mental health assistance, siblings (n = 21) and population-based controls (n = 35). Bisulfite conversion and pyrosequencing were used to determine methylation levels in 4 CpG sites in promoter sequence of PVALB and 5 CpG sites at GRIN2B (gene which encodes NR2).
S13. DO PATIENTS WITH RECENT-ONSET

S14. DNA METHYLATION CHANGES IN GABAERGIC AND GLUTAMATERGIC MARKERS
Results:
We found hypermethylation at a CpG site within the PVALB promoter sequence in patients and their siblings compared to populationbased control group (p< 0.001) while overall hypomethylation was found in the 5 CpGs analysed within GRIN2B promoter sequence (p < 0.01). Discussion: Our PVALB findings are consistent with our previous studies showing that PVALB promoter methylation is elevated in schizophrenia and, additionally this is the first evidence showing changes in GRIN2B promoter methylation in psychosis. These results together suggest that these epigenetic findings may relate to the reduction of protein expression of indicators of glutamate and GABA systems seen in this disease. Background: To investigate whether the eye movement pattern is different between facial emotion recognition and real social scene emotion recognition, and which can better reflect the social function and the clinical symptoms using a novel theme identification task.
S15. ABNORMAL EYE TRACKING IN PATIENTS
Methods: Total 29 patients with schizophrenia and 31 healthy controls completed the theme identification task, in which subjects selected which word, out of positive, neutral and negative, described the theme of a picture under facial emotion recognition and real social scene emotion recognition. Positive and negative syndrome scale (PANSS) and social function in psychosis inpatients (SSPI) were used to assess the symptom and social function. Results: The schizophrenia's eye movement paradigms under both facial emotion and social scene show decreased number of fixation (t=-3.49, P=0.00; t=-3.62, P=0.00), decreased number of saccades (t=-3.15, P=0.00; t=-3.72, P=0.00), decreased scan path length (t=-2.23, P=0.03; t=-4.18, P=0.03), decreased fixation number in interest area (t=3.01, P=0.00; t=-3.24, P=0.00). Different from facial emotion cognition, the eye movement under social scene cognition showed lower percentage of fixation number in interest area than that in healthy subjects (P=0.01), furthermore, the length of scan path under the negative social scene pictures was associated with the total score of SSPI (r=-0.38, P=0.04), the PANSS total score (r=-0.46, P=0.01), the positive symptoms score (r=-0.39, P=0.04), the general score (r=-0.50, P=0.01). Discussion: The patients showed more abnormal eye tracking indicators under social scene than facial emotion. Under negative emotion social scene, the length of scan path related to social function and clinical symptoms, it may be a potential indicator to evaluate social function and degree of disease.
